Creatine in Perimenopause: Brain Energy & the 2025 RCT

For women navigating perimenopause and menopause, brain fog is not just an anecdote — it is a measurable cognitive shift tied to falling estrogen and declining cerebral energy metabolism. A 2025 randomized controlled trial — the CONCRET-MENOPA study — now provides the most direct clinical evidence yet that creatine perimenopause supplementation can meaningfully restore frontal brain creatine levels, sharpen reaction time, and potentially ease mood swings. And it does so without a single gram of added sugar.

Why Menopause Disrupts Brain Energy

The link between estrogen and brain energy metabolism runs deeper than most people realize. Estrogen upregulates two of the three enzymes responsible for endogenous creatine biosynthesis — arginine:glycine amidinotransferase (AGAT) and guanidinoacetate N-methyltransferase (GAMT). As estrogen declines during perimenopause, endogenous creatine production falls in parallel, reducing the brain's phosphocreatine (PCr) buffer — the rapid-cycling energy reservoir that regenerates ATP during periods of high neuronal demand.

Neuroimaging studies have documented lower brain creatine concentrations in postmenopausal women compared with premenopausal controls, particularly in the prefrontal cortex — a region central to working memory, processing speed, and executive function. This bioenergetic deficit likely contributes to the subjective cognitive complaints (brain fog, word-finding difficulty, reduced concentration) that up to 60% of perimenopausal women report.

How the Phosphocreatine System Works in the Brain

To understand why creatine supplementation may help, it helps to understand the creatine–phosphocreatine shuttle. In high-energy tissues like the brain, the enzyme creatine kinase (brain isoform: CK-BB) catalyzes the reversible transfer of a phosphate group between creatine and ATP:

PCr + ADP ⇌ Creatine + ATP

Phosphocreatine acts as both a temporal energy buffer — covering sudden ATP demand spikes during intense cognitive work — and a spatial buffer, shuttling energy from mitochondria to sites of active consumption. When PCr stores are depleted through metabolic stress, sleep deprivation, or the hormonal shifts of menopause, neuronal function degrades measurably. Oral creatine supplementation raises brain creatine concentrations by approximately 5–15%, depending on dose, form, and baseline status, as documented across multiple ¹H-MRS neuroimaging studies.

The CONCRET-MENOPA Trial: Study Design

The CONCRET-MENOPA trial, published in the Journal of the American Nutrition Association (2025), was a randomized, placebo-controlled study enrolling 36 apparently healthy perimenopausal and menopausal women (mean age 50.1 ± 5.7 years). Participants were randomized to one of four 8-week interventions:

• Low-dose creatine hydrochloride (750 mg/day)
• Medium-dose creatine hydrochloride (1,500 mg/day)
• Combination: creatine HCl + creatine ethyl ester (800 mg/day total)
• Placebo

Primary endpoints included frontal lobe brain creatine concentration measured via proton magnetic resonance spectroscopy (¹H-MRS), reaction time, a standardized cognitive battery, serum lipid profiles, and mood symptom severity scales. All four interventions were well tolerated, with no severe adverse effects reported in any group.

Key Findings: Brain Creatine, Reaction Time, and Mood

The medium-dose creatine hydrochloride arm produced statistically significant advantages over placebo across three primary domains:

• Frontal brain creatine concentration: +16.4% increase vs. +0.9% in placebo (p < 0.01) — a substantial elevation of the prefrontal PCr reservoir.
• Reaction time: improved by 6.6% vs. 1.2% in placebo (p < 0.01), reflecting measurably faster neural processing speed.
• Serum lipid profile: favorable modulation of lipid markers (p < 0.05), consistent with creatine's known role in hepatic methyl-group donation that spares S-adenosyl methionine (SAM) for broader metabolic use.
• Mood swings: a trend toward reduced severity versus all other groups (p = 0.06) — approaching but not reaching conventional significance, likely due to the study's 8-week duration and modest sample size.

Critically, the low-dose and combination arms did not significantly outperform placebo on primary cognitive endpoints, underscoring the importance of adequate creatine dosing. These trial results align closely with a 2025 systematic review in Nutrition Reviews (Oxford Academic) which concluded that creatine supplementation shows promising — if still preliminary — benefits for cognitive function in aging adults, particularly under conditions of metabolic stress.

Creatine Dose: What the Safety Data Shows

The CONCRET-MENOPA findings naturally raise a follow-up question: if 1,500 mg/day creatine HCl produced meaningful brain creatine elevations, would higher doses — including the 5g/day creatine monohydrate standard widely used in exercise science — produce even greater benefit?

The mechanistic and safety evidence leans toward yes. A 2025 analysis of data from 684 randomized controlled trials involving more than 12,800 participants found that higher creatine doses and longer supplementation durations were not associated with increased adverse events — reinforcing the robust safety profile of creatine at clinically meaningful doses. A 2025 commentary in Frontiers in Nutrition similarly concluded that for brain bioenergetic endpoints specifically, doses of 3–5 g/day creatine monohydrate appear to produce the most consistent, neuroimaging-confirmed brain creatine elevations.

Creatine monohydrate at 5g/day remains the gold-standard form backed by the deepest evidence base for both bioavailability and central nervous system uptake.

Broader Context: Creatine, Aging, and Hippocampal Plasticity

The CONCRET-MENOPA trial sits within a broader, converging body of evidence. A 2025 study in PMC demonstrated that long-term creatine supplementation improved cognitive impairment and hippocampal structural plasticity in an accelerated-aging model, with the mechanism linked to increased CK-BB activity — the same brain-specific creatine kinase isoform relevant to the estrogen-creatine axis in perimenopausal women. The hippocampus governs declarative memory and spatial navigation, two cognitive domains commonly reported to decline during the menopause transition.

Taken together, the evidence points to a coherent mechanism: declining estrogen → reduced endogenous creatine synthesis → lower brain PCr → measurable cognitive degradation → potentially reversible with exogenous creatine supplementation at adequate doses.

What the Evidence Doesn't Yet Tell Us

Intellectual honesty requires acknowledging the limitations. CONCRET-MENOPA enrolled 36 participants over 8 weeks — adequately powered for its primary endpoints, but not sufficient to draw conclusions about long-term cognitive outcomes, optimal dose-response curves specific to perimenopausal women, or which cognitive domains benefit most. The doses studied (up to 1,500 mg/day creatine HCl) are lower than the 3–5 g/day monohydrate standard in sports science, making precise cross-study dose comparisons difficult.

Larger, longer RCTs — ideally stratifying participants by hormonal status, baseline brain creatine levels, and AGAT/GAMT genotype — are needed before clinical guidelines can be established. What is currently well-supported: the biological plausibility is robust, brain creatine elevations with supplementation are measurable and consistent, and the safety record at doses far above those tested is strong.